# TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir

> **NCT01241773** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 48 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** raltegravir
- **DRUG:** TMC435 + raltegravir
- **DRUG:** TMC435
- **DRUG:** TMC435 + efavirenz
- **DRUG:** TMC435
- **DRUG:** efavirenz

## Key facts

- **NCT ID:** NCT01241773
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01241773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01241773, "TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01241773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*